Alterity Therapeutics Ltd has released a press release.
Prospectus filed pursuant to SEC Rule 424(b)(3)
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Chairmans Address 2020 Annual General Meeting
- US patent for next generation neurodegenerative diseases
- MSA patients enrolled in bioMUSE Study
- Alterity completes Placement Tranche 1 raising $10M
- Alterity raises $35M in placement to institutional investors
Later from Alterity Therapeutics
- Alterity presents at Finance News Network
- New commercial opportunity for PBT2
- Form F-3
- Dr David Stamler Appointed CEO
- Alterity participates in JP Morgan healthcare conference
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics